ALFA USA News
Straight from the SEC filing
Every SEC filing by PULSE BIOSCIENCES, INC. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (14 Oct 2026). Not a valuation or a recommendation.
Down 10.5% over the last month ($54.21 on 14 Sep → $48.54 on 13 Oct). Daily closing prices. Source: Yahoo Finance.
| 14 Sep | $54.21 |
|---|---|
| 15 Sep | $55.20 |
| 16 Sep | $49.61 |
| 17 Sep | $50.61 |
| 18 Sep | $53.87 |
| 21 Sep | $53.31 |
| 22 Sep | $52.69 |
| 23 Sep | $51.98 |
| 24 Sep | $51.83 |
| 25 Sep | $51.63 |
| 28 Sep | $52.32 |
| 29 Sep | $50.89 |
| 30 Sep | $49.92 |
| 1 Oct | $49.83 |
| 2 Oct | $47.90 |
| 5 Oct | $50.50 |
| 6 Oct | $49.75 |
| 7 Oct | $49.09 |
| 8 Oct | $49.98 |
| 9 Oct | $53.81 |
| 12 Oct | $52.45 |
| 13 Oct | $48.54 |
Pulse Biosciences (PLSE) partners with Clayman Thyroid Center to deploy nPulse Vybrance for thyroid nodules, targeting a $3.46B market cap healthcare expansion.
Pulse Biosciences reached its 164-patient enrollment target for the NANOPULSE-AF pivotal study three months early, advancing its cardiac catheter development.
Track PULSE BIOSCIENCES, INC. live
Get the next PULSE BIOSCIENCES, INC. SEC filing seconds after it lands.
